Deciphera’s Vimseltinib Could Benefit From Liver Safety, Prescriber Overlap in TGCT
Executive Summary
Positive topline results from the Phase III MOTION trial showed none of the liver toxicity that earned Daiichi Sankyo’s Turalio a boxed warning and REMS in tenosynovial giant cell tumor.